FGL

Overview

FGL is a synthetic peptide derived from the second fibronectin type III module of neural cell adhesion molecule (NCAM). It mimics the interaction between NCAM and fibroblast growth factor receptor 1 (FGFR1), activating downstream signaling cascades that promote synaptic plasticity, neurogenesis, and neuroprotection. Research has primarily been conducted in animal models, where FGL has shown promise for cognitive enhancement, stroke recovery, and neurodegenerative disease models.

Mechanism of action

FGL binds to and activates FGFR1, triggering receptor autophosphorylation and downstream signaling through the MAPK/ERK and PI3K/Akt pathways. This activation promotes long-term potentiation (LTP), enhances synaptic plasticity, stimulates neurogenesis in the hippocampus, and provides neuroprotective effects against excitotoxicity and oxidative stress.

Key research findings

• Activates FGFR1 to promote synaptic plasticity
• Stimulates hippocampal neurogenesis
• Provides neuroprotection against excitotoxic and ischemic injury
• Enhances long-term potentiation (LTP) in preclinical models
• Potential cognitive enhancement via NCAM-mimetic signaling

Research applications

Cognitive

• Memory and Learning — Enhances memory consolidation and spatial learning in animal models through FGFR1-mediated synaptic plasticity.
• Cognitive Decline — Preclinical evidence suggests potential to counteract age-related cognitive decline via neurogenesis and synaptic support.

Neuroprotection

• Stroke Recovery — Animal studies demonstrate reduced infarct volume and improved functional outcomes following ischemic injury.
• Neurodegenerative Disease Models — Shows protective effects in preclinical models of Alzheimer’s disease and other neurodegenerative conditions.

Neuroplasticity

• Synaptic Plasticity — Promotes long-term potentiation and strengthens synaptic connections through FGFR1 activation.
• Neurogenesis — Stimulates the generation of new neurons in the hippocampus in animal models.